xalkori
pfizer europe ma eeig - crizotinib - carcinoma, pulmón no microcítico - agentes antineoplásicos - xalkori as monotherapy is indicated for:the first‑line treatment of adults with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with previously treated anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with ros1‑positive advanced non‑small cell lung cancer (nsclc)the treatment of paediatric patients (age ≥6 to.
xalkori 200 mg capsulas
pfizer venezuela, s.a. - crizotinib - c - 200 mg
xalkori 250 mg c
pfizer venezuela ,s.a - crizotinib - c - 250 mg